A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling.

Persistent STAT3 activation has been found in activated B-cell like diffuse large B cell tumors (DLBCL). To investigate whether genetic mutations play a role in aberrant STAT3 signaling in DLBCL, we bi-directionally sequenced all 24 exons of the STAT3 gene in DLBCL tumors (n = 40). We identified 2 n...

Full description

Bibliographic Details
Main Authors: Guangzhen Hu, Thomas E Witzig, Mamta Gupta
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2013-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3701620?pdf=render
_version_ 1831563419407351808
author Guangzhen Hu
Thomas E Witzig
Mamta Gupta
author_facet Guangzhen Hu
Thomas E Witzig
Mamta Gupta
author_sort Guangzhen Hu
collection DOAJ
description Persistent STAT3 activation has been found in activated B-cell like diffuse large B cell tumors (DLBCL). To investigate whether genetic mutations play a role in aberrant STAT3 signaling in DLBCL, we bi-directionally sequenced all 24 exons of the STAT3 gene in DLBCL tumors (n = 40). We identified 2 novel point mutations in 2 separate (2/40; 5%) patients at exon 7 and 24. Point mutation 2552G>A was a silent mutation in the stop codon. Another heterozygous mutation 857T>A encoded a methionine substitution by lysine at codon 206 (M206K) in the coiled-coil domain of STAT3. We performed site directed mutagenesis to mutate wild type (WT) STAT3α and STAT3β at codon 206 and constructed stable cell lines by lentiviral transfection of STAT3α(WT), STAT3α(M206K), STAT3β(WT) and STAT3β(M206K) plasmids. The mutation was found to increase STAT3 phosphorylation in STAT3α mutant cell lines with no effect on the STAT3β mutant cell line. Transcriptional activation was also increased in the STAT3α mutant cells compared with STAT3α WT cells as detected by a luciferase reporter assay. Moreover, STAT3α(M206K) mutant cells were resistant to JAK2 pathway inhibition compared to STAT3α WT cells. These results indicate that missense mutations in STAT3 increase signaling through the JAK/STAT pathway. JAK2 inhibitors may be useful in the patient with this STAT3 mutation as well as those with pathway activation by other mechanisms.
first_indexed 2024-12-17T10:54:54Z
format Article
id doaj.art-bf172745fb9145cb95dee7b8d26150e9
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-17T10:54:54Z
publishDate 2013-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-bf172745fb9145cb95dee7b8d26150e92022-12-21T21:51:51ZengPublic Library of Science (PLoS)PLoS ONE1932-62032013-01-0187e6785110.1371/journal.pone.0067851A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling.Guangzhen HuThomas E WitzigMamta GuptaPersistent STAT3 activation has been found in activated B-cell like diffuse large B cell tumors (DLBCL). To investigate whether genetic mutations play a role in aberrant STAT3 signaling in DLBCL, we bi-directionally sequenced all 24 exons of the STAT3 gene in DLBCL tumors (n = 40). We identified 2 novel point mutations in 2 separate (2/40; 5%) patients at exon 7 and 24. Point mutation 2552G>A was a silent mutation in the stop codon. Another heterozygous mutation 857T>A encoded a methionine substitution by lysine at codon 206 (M206K) in the coiled-coil domain of STAT3. We performed site directed mutagenesis to mutate wild type (WT) STAT3α and STAT3β at codon 206 and constructed stable cell lines by lentiviral transfection of STAT3α(WT), STAT3α(M206K), STAT3β(WT) and STAT3β(M206K) plasmids. The mutation was found to increase STAT3 phosphorylation in STAT3α mutant cell lines with no effect on the STAT3β mutant cell line. Transcriptional activation was also increased in the STAT3α mutant cells compared with STAT3α WT cells as detected by a luciferase reporter assay. Moreover, STAT3α(M206K) mutant cells were resistant to JAK2 pathway inhibition compared to STAT3α WT cells. These results indicate that missense mutations in STAT3 increase signaling through the JAK/STAT pathway. JAK2 inhibitors may be useful in the patient with this STAT3 mutation as well as those with pathway activation by other mechanisms.http://europepmc.org/articles/PMC3701620?pdf=render
spellingShingle Guangzhen Hu
Thomas E Witzig
Mamta Gupta
A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling.
PLoS ONE
title A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling.
title_full A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling.
title_fullStr A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling.
title_full_unstemmed A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling.
title_short A novel missense (M206K) STAT3 mutation in diffuse large B cell lymphoma deregulates STAT3 signaling.
title_sort novel missense m206k stat3 mutation in diffuse large b cell lymphoma deregulates stat3 signaling
url http://europepmc.org/articles/PMC3701620?pdf=render
work_keys_str_mv AT guangzhenhu anovelmissensem206kstat3mutationindiffuselargebcelllymphomaderegulatesstat3signaling
AT thomasewitzig anovelmissensem206kstat3mutationindiffuselargebcelllymphomaderegulatesstat3signaling
AT mamtagupta anovelmissensem206kstat3mutationindiffuselargebcelllymphomaderegulatesstat3signaling
AT guangzhenhu novelmissensem206kstat3mutationindiffuselargebcelllymphomaderegulatesstat3signaling
AT thomasewitzig novelmissensem206kstat3mutationindiffuselargebcelllymphomaderegulatesstat3signaling
AT mamtagupta novelmissensem206kstat3mutationindiffuselargebcelllymphomaderegulatesstat3signaling